FDA label f357550a-7880-4300-b992-a9dd56d03750

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
d8e5364a-ac4c-4715-979b-21c9f535d12c
SPL ID
f357550a-7880-4300-b992-a9dd56d03750
Version
2
Effective date
2020-05-31
Source export date
2026-10-12
Source partition
4
Source file
https://download.open.fda.gov/drug/label/drug-label-0004-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/b939c18fdf51df171cf60ce5558819d08ac66bb16bb9991d48cbec91028d783e/drug-label-0004-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 01:35:40

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Do not exceed recommended dose. Methenamine may combine with sulfonamides in the urine to give mutual antagonism and should not be used with sulfonamides.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Prolonged use may result in a generalized skin rash, pronounced dryness of the mouth, flushing, difficulty in initiating micturition, rapid pulse, dizziness or blurring of vision. If any of these reactions occurs, discontinue use immediately. Acute urinary retention may be precipitated in prostatic hypertrophy. See “OVERDOSE”.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.